Johns Hopkins Medicine scientists say they have found new evidence in lab-grown mouse brain cells, called astrocytes, that one root of Alzheimer's disease may be a simple imbalance in acid-alkaline—or pH—chemistry inside ...
Aug 2, 2018
0
224
University of Oxford researchers assessed evidence from 34 studies, involving more than 57,000 pregnant women with HIV, and found that protease inhibitor-based antiretroviral therapies significantly increased the risk of ...
Apr 12, 2022
0
30
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently ...
Jul 8, 2020
0
113
The growth of solid tumors is frequently driven by mutations in key proto-oncogenes. For non-small-cell lung cancers (NSCLC), somatic mutations in the KRAS (Kirsten RAt Sarcoma virus) gene turn it into an oncogene that renders ...
An LMU team has identified an enzyme that is essential for DNA repair. Loss of this factor leads to cell death when cancer cells accumulate DNA damage. Chemical inhibition of the target protein offers a possible strategy ...
Dec 4, 2020
0
219
A DNA mutation that occurs frequently in the development of many pancreatic tumors appears to make these cancers vulnerable to an existing type of drug known as PARP inhibitors, according to a new study from scientists in ...
Dec 15, 2020
0
1437
A unique bacterial strain isolated from a patient with pelvic pain may represent a promising path to treating prostate cancer with immunotherapy, according to a Northwestern Medicine study published in Nature Communications.
Jun 7, 2018
0
204
Unleashing the immune system to fight tumors—an approach enabled by immunotherapy—has led to remarkable outcomes in some cancer patients, but in many more, cancer cells evade the treatment and continue to spread. Now, ...
Nov 2, 2018
0
64
Use of sodium glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes may help to lower the risk of serious kidney problems, finds a study published by The BMJ today.
Apr 29, 2020
0
33
Researchers at Memorial Sloan Kettering Cancer Center, New York, have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib.
